

SESN1,2,3 bind overoxidized PRDX1

Hwang, PM., Inga, A., Kang, JG., Orlic-Milacic, M., Wang, PY., Zaccara, S.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](#). For more information see our [license](#).

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 77


This document contains 1 reaction ([see Table of Contents](#))

SESN1,2,3 bind overoxidized PRDX1 [↗](#)

Stable identifier: R-HSA-5631903

Type: binding

Compartments: cytosol



Sestrins (SESN1, SESN2 and likely SESN3) bind overoxidized PRDX1, in which the catalytic cysteine C52 has been converted to cysteine-sulfinic acid. Among all peroxiredoxins, PRDX1 is the most abundant member of the PRDX family. The major function is to protect cells against reactive oxygen species (ROS), thus impacting on cell proliferation and survival (Gong et al. 2015). While several reports state that sestrins reduce overoxidized PRDX1 to the catalytically active homodimer (Budanov et al. 2004, Papadia et al. 2008, Essler et al. 2009), there are conflicting reports claiming that sestrins do not possess cysteine sulfinyl reductase activity (Woo et al. 2009).

Literature references

- Papadia, S., Soriano, FX., Léveillé, F., Martel, MA., Dakin, KA., Hansen, HH. et al. (2008). Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. *Nat. Neurosci.*, 11, 476-87. [↗](#)
- Essler, S., Dehne, N., Brüne, B. (2009). Role of sestrin2 in peroxide signaling in macrophages. *FEBS Lett.*, 583, 3531-5. [↗](#)
- Woo, HA., Bae, SH., Park, S., Rhee, SG. (2009). Sestrin 2 is not a reductase for cysteine sulfinic acid of peroxiredoxins. *Antioxid. Redox Signal.*, 11, 739-45. [↗](#)
- Budanov, AV., Sablina, AA., Feinstein, E., Koonin, EV., Chumakov, PM. (2004). Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. *Science*, 304, 596-600. [↗](#)
- Gong, F., Hou, G., Liu, H., Zhang, M. (2015). Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma. *Med. Oncol.*, 32, 455. [↗](#)

Editions

| | | |
|------------|------------------|----------------------------------|
| 2014-12-23 | Authored, Edited | Orlic-Milacic, M. |
| 2014-12-30 | Reviewed | Hwang, PM., Kang, JG., Wang, PY. |
| 2016-02-04 | Reviewed | Inga, A., Zaccara, S. |